CIRM awards $8m grant to Tr1X for trial of GvHD prevention drug candidate TRX103

CIRM awards $8m grant to Tr1X for trial of GvHD prevention drug candidate TRX103
The California Institute for Regenerative Medicine (CIRM) has granted $8m to Tr1X for their Phase I/IIa trial of TRX103, a drug to prevent GvHD in blood cancer patients undergoing stem cell transplants.